{'fraction_non_alphanumeric': 0.022321428571428572, 'fraction_numerical': 0.00744047619047619, 'mean_word_length': 4.65546218487395, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Patients with m2 antibodies: what diagnosis and follow-up are they given?

In a recent issue of Gut Feuchinger et al report a novel marker antibody for primary biliary cirrhosis (PBC) which may become useful in the diagnosis of PBC in the future.1 At present diagnosis is based on the presence of the M2 substrate of anti-mitochondrial antibody (AMA) in the sera and liver function tests. The American Association for the Study of Liver Disease (AASLD) recommend that a diagnosis of PBC can be made with a positive M2 antibody and cholestatic liver biochemistry (biopsy can be used to confirm) and that patients who are M2 positive only should be followed up with annual …